One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Is it time to homogenize the living kidney donation informed consent?
Luis E Morales-Buenrostro, Monica Sánchez-Cárdenas, Abraham Cohen-Bucay
doi : 10.1093/ndt/gfab199
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1557–1558
A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35?years
Francesco Locatelli, Lucia Del Vecchio
doi : 10.1093/ndt/gfab177
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1559–1563
Trajectories of quality of life in chronic kidney disease: a novel perspective of disease progression
Noa Amir, Allison Tong, Hugh McCarthy, Martin Howell
doi : 10.1093/ndt/gfab006
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1563–1565
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?
Hassan Izzedine, Marco Bonilla, Kenar D Jhaveri
doi : 10.1093/ndt/gfab215
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1565–1569
Prerenal acute kidney injury—still a relevant term in modern clinical practice?
Anthony Bonavia, Gregory Vece, Kunal Karamchandani
doi : 10.1093/ndt/gfaa061
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1570–1577
The traditional taxonomy of acute kidney injury (AKI) has remained pervasive in clinical nephrology. While the terms ‘prerenal’, ‘intrarenal’ and ‘postrenal’ highlight the diverse pathophysiology underlying AKI, they also imply discrete disease pathways and de-emphasize the nature of AKI as an evolving clinical syndrome with multiple, often simultaneous and overlapping, causes. In a similar vein, prerenal AKI comprises a diverse spectrum of kidney disorders, albeit one that is often managed by using a standardized clinical algorithm. We contend that the term ‘prerenal’ is too vague to adequately convey our current understanding of hypoperfusion-related AKI and that it should thus be avoided in the clinical setting. Practice patterns among nephrologists indicate that AKI-related terminology plays a significant role in the approaches that clinicians take to patients that have this complex disease. Thus, it appears that precise terminology does impact the treatment that patients receive. We will outline differences in the diagnosis and management of clinical conditions lying on the so-called prerenal disease spectrum to advocate caution when administering intravenous fluids to these clinically decompensated patients. An understanding of the underlying pathophysiology may, thus, avert clinical missteps such as fluid and vasopressor mismanagement in tenuous or critically ill patients.
Midkine and chronic kidney disease-associated multisystem organ dysfunctions
Victoria K Campbell, Ryan P Gately, Rathika Krishnasamy, Dominic Burg, Graham R Robertson, Nicholas A Gray
doi : 10.1093/ndt/gfaa084
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1577–1584
Chronic kidney disease (CKD) is a progressive multisystem condition with yet undefined mechanistic drivers and multiple implicated soluble factors. If identified, these factors could be targeted for therapeutic intervention for a disease that currently lacks specific treatment. There is increasing preclinical evidence that the heparin/endothelial glycocalyx-binding molecule midkine (MK) has a pathological role in multiple CKD-related, organ-specific disease processes, including CKD progression, hypertension, vascular and cardiac disease, bone disease and CKD-related cancers. Concurrent with this are studies documenting increases in circulating and urine MK proportional to glomerular filtration rate (GFR) loss in CKD patients and evidence that administering soluble MK reverses the protective effects of MK deficiency in experimental kidney disease. This review summarizes the growing body of evidence supporting MK’s potential role in driving CKD-related multisystem disease, including MK’s relationship with the endothelial glycocalyx, the deranged MK levels and glycocalyx profile in CKD patients and a proposed model of MK organ interplay in CKD disease processes and highlights the importance of ongoing research into MK’s potential as a therapeutic target.
Distal renal tubular acidosis: ERKNet/ESPN clinical practice points
Francesco Trepiccione, Steven B Walsh, Gema Ariceta, Olivia Boyer, Francesco Emma, Roberta Camilla, Pietro Manuel Ferraro, Dieter Haffner, Martin Konrad, Elena Levtchenko, Sergio Camilo Lopez-Garcia, Fernando Santos, Stella Stabouli, Maria Szczepanska, Velibor Tasic, Rezan Topaloglu, Rosa Vargas-Poussou, Tanja Wlodkowski, Detlef Bockenhauer
doi : 10.1093/ndt/gfab171
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1585–1596
Distal renal tubular acidosis (dRTA) is characterized by an impaired ability of the distal tubule to excrete acid, leading to metabolic acidosis. Associated complications include bone disease, growth failure, urolithiasis and hypokalaemia. Due to its rarity, there is limited evidence to guide diagnosis and management; however, available data strongly suggest that metabolic control of the acidosis by alkali supplementation can halt or revert almost all complications. Despite this, cohort studies show that adequate metabolic control is present in only about half of patients, highlighting problems with treatment provision or adherence. With these clinical practice points the authors, part of the working groups tubulopathies in the European Rare Kidney Disease Reference network and inherited kidney diseases of the European Society for Paediatric Nephrology, aim to provide guidance for the management of patients with dRTA to facilitate adequate treatment and establish an initial best practice standard against which treatment of patients can be audited.
The role of the kidney in AL amyloidosis
Priya P Deshpande, Kenar D Jhaveri
doi : 10.1093/ndt/gfz240
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1597–1599
The genetics of steroid-resistant nephrotic syndrome in adults
Olivia Boyer, Guillaume Dorval, Aude Servais
doi : 10.1093/ndt/gfz257
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1600–1602
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis
Qiyan Zheng, Huisheng Yang, Xinwen Fu, Yishan Huang, Ruojun Wei, Yahui Wang, Yu Ning Liu, Wei Jing Liu
doi : 10.1093/ndt/gfaa110
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1603–1615
Chronic kidney disease (CKD) is an increasing public health issue. Anemia, which is a complication of CKD, is associated with reduced quality of life and increased morbidity and mortality. Currently quite a few clinical studies have been conducted to compare roxadustat with epoetin alfa [all for dialysis-dependent (DD) patients] or placebo [all for nondialysis-dependent (NDD) patients]. Our meta-analysis aimed to investigate the efficacy and safety of roxadustat for anemia in patients with CKD.
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch, Udaya Valluri, Christophe Mariat
doi : 10.1093/ndt/gfab191
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1616–1628
Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD).
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
Evgeny Shutov, W?adys?aw Su?owicz, Ciro Esposito, Avtandil Tataradze, Branislav Andric, Michael Reusch, Udaya Valluri, Nada Dimkovic
doi : 10.1093/ndt/gfab057
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1629–1639
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia.
Dietary plant and animal protein intake and decline in estimated glomerular filtration rate among elderly women: a 10-year longitudinal cohort study
Amélie Bernier-Jean, Richard L Prince, Joshua R Lewis, Jonathan C Craig, Jonathan M Hodgson, Wai H Lim, Armando Teixeira-Pinto, Germaine Wong
doi : 10.1093/ndt/gfaa081
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1640–1647
Many older women demonstrate an age-related accelerating rate of renal decline that is associated with increased rates of bone disease, cardiovascular disease and mortality. Population-based protein restriction has been studied principally in patients with reduced renal function. In this investigation, we examined the hypothesis of a differential effect of plant-derived protein compared with animal-derived protein on renal function in older women.
Direct Renin Inhibition in Non-diabetic chronic Kidney disease (DRINK): a prospective randomized trial
Sydney C W Tang, Kam Wa Chan, Dennis K M Ip, Desmond Y H Yap, Maggie K M Ma, Maggie M Y Mok, Gary C W Chan, Sidney Tam, Kar Neng Lai
doi : 10.1093/ndt/gfaa085
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1648–1656
The potential long-term safety and efficacy of aliskiren in nondiabetic chronic kidney disease (CKD) are unknown. We sought to investigate the renoprotective effect of aliskiren on nondiabetic CKD patients.
Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study
Nicholas C Chesnaye, Friedo W Dekker, Marie Evans, Fergus J Caskey, Claudia Torino, Maurizio Postorino, Maciej Szymczak, Chava L Ramspek, Christiane Drechsler, Christoph Wanner, Kitty J Jager the EQUAL study investigators
doi : 10.1093/ndt/gfaa095
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1656–1663
Understanding the mechanisms underlying the differences in renal decline between men and women may improve sex-specific clinical monitoring and management. To this end, we aimed to compare the slope of renal function decline in older men and women in chronic kidney disease (CKD) Stages 4 and 5, taking into account informative censoring related to the sex-specific risks of mortality and dialysis initiation.
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort
Claire Stein, Stéphane Burtey, Julien Mancini, Marion Pelletier, Marion Sallée, Philippe Brunet, Philippe Berbis, Jean Jacques Grob, Stéphane Honoré, Caroline Gaudy, Noémie Jourde-Chiche
doi : 10.1093/ndt/gfaa137
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1664–1674
Immune checkpoints inhibitors have transformed the prognosis of advanced melanoma but are associated with immune-related adverse events (irAEs). We evaluated the incidence, risk factors and causes of acute kidney injury (AKI) in a monocentric real-life cohort of patients treated with anti-programmed death receptor-1 (anti-PD1) antibodies for advanced melanoma.
Metagenomic profiling of gut microbiome in early chronic kidney disease
Noriaki Sato, Masanori Kakuta, Takanori Hasegawa, Rui Yamaguchi, Eiichiro Uchino, Koichi Murashita, Shigeyuki Nakaji, Seiya Imoto, Motoko Yanagita, Yasushi Okuno
doi : 10.1093/ndt/gfaa122
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1675–1684
The relationship between chronic kidney disease (CKD) and the gut microbiome, which interact through chronic inflammation, uraemic toxin production and immune response regulation, has gained interest in the development of CKD therapies. However, reports using shotgun metagenomic analysis of the gut microbiome are scarce, especially for early CKD. Here we characterized gut microbiome differences between non-CKD participants and ones with early CKD using metagenomic sequencing.
Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study
Morgan E Grams, Aditya Surapaneni, Lawrence J Appel, James P Lash, Jesse Hsu, Clarissa J Diamantidis, Sylvia E Rosas, Jeffrey C Fink, Julia J Scialla, James Sondheimer, Chi-Yuan Hsu, Alfred K Cheung, Bernard G Jaar, Sankar Navaneethan, Debbie L Cohen, Sarah Schrauben, Dawei Xie, Pandu Rao, Harold I Feldman, the CRIC study investigators
doi : 10.1093/ndt/gfaa364
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1685–1693
Patients with chronic kidney disease (CKD) face risks of not only end-stage kidney disease (ESKD), cardiovascular disease (CVD) and death, but also decline in kidney function, quality of life (QOL) and mental and physical well-being. This study describes the multidimensional trajectories of CKD using clinical events, kidney function and patient-reported outcome measures (PROMs). We hypothesized that more advanced CKD stages would associate with more rapid decline in each outcome.
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia
Murilo Guedes, Daniel Muenz, Jarcy Zee, Marcelo Barreto Lopes, Sandra Waechter, Bénédicte Stengel, Ziad A Massy, Elodie Speyer, Carole Ayav, Fredric Finkelstein, Ricardo Sesso, Ronald L Pisoni, Bruce M Robinson, Roberto Pecoits-Filho
doi : 10.1093/ndt/gfab050
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1694–1703
Iron deficiency (ID) is a common condition in nondialysis-dependent chronic kidney disease (NDD-CKD) patients that is associated with poorer clinical outcomes. However, the effect of ID on health-related quality of life (HRQoL) in this population is unknown. We analyzed data from a multinational cohort of NDD-CKD Stages 3–5 patients to test the association between transferrin saturation (TSAT) index and ferritin with HRQoL.
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
Nathalie Longlune, Marie Béatrice Nogier, Marcel Miedougé, Charlotte Gabilan, Charles Cartou, Bruno Seigneuric, Arnaud Del Bello, Olivier Marion, Stanislas Faguer, Jacques Izopet, Nassim Kamar
doi : 10.1093/ndt/gfab193
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1704–1709
Patients with chronic kidney disease, dialysis patients and kidney transplant patients are at high risk of developing severe coronavirus disease 2019 (COVID-19). Data regarding the immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 messenger RNA (anti-SARS-CoV-2 mRNA) vaccines in dialysis patients were published recently. We assessed the immunogenicity of anti-SARS-CoV-2 mRNA vaccine in dialysis patients.
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls
Benedikt Simon, Harald Rubey, Andreas Treipl, Martin Gromann, Boris Hemedi, Sonja Zehetmayer, Bernhard Kirsch
doi : 10.1093/ndt/gfab179
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1709–1716
Haemodialysis (HD) patients are exposed to a high risk due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. They are prone to acquiring the infection and are threatened by high mortality rates in case of infection. However, HD patients were not included in the efficacy trials of the SARS-CoV-2 vaccines. Such efficacy data would have been critical because HD patients show decreased responses against various other vaccines and this could translate to the SARS-CoV-2 vaccines as well.
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
Robert Provenzano, Evgeny Shutov, Liubov Eremeeva, Svitlana Korneyeva, Lona Poole, Gopal Saha, Charles Bradley, Meraf Eyassu, Anatole Besarab, Robert Leong, Cameron S Liu, Thomas B Neff, Lynda Szczech, Kin-Hung P Yu
doi : 10.1093/ndt/gfab051
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1717–1730
We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis.
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
Masaomi Nangaku, Kazuoki Kondo, Kiichiro Ueta, Yoshimasa Kokado, Genki Kaneko, Hiroki Matsuda, Yutaka Kawaguchi, Yasuhiro Komatsu
doi : 10.1093/ndt/gfab055
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1731–1741
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis.
Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups
Geir Mjøen, Umberto Maggiore, Nicos Kessaris, Diederik Kimenai, Bruno Watschinger, Cristophe Mariat, Mehmet Sukru Sever, Marta Crespo, Licia Peruzzi, Goce Spasovski, Søren Schwartz Sørensen, Uwe Heemann, Julio Pascual, Ondrej Viklicky, Aisling E Courtney, Karine Hadaya, Laszlo Wagner, Ionut Nistor, Vassilis Hadjianastassiou, Magdalena Durlik, Ilkka Helanterä, Rainer Oberbauer, Gabriel Oniscu, Luuk Hilbrands, Daniel Abramowicz for the European Renal Association – European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) working group and the European Society of Organ Transplantation (ESOT) European Kidney Transplant Association (EKITA)—collaborators are listed in the Appendix
doi : 10.1093/ndt/gfab035
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1742–1753
Publications from the last decade have increased knowledge regarding long-term risks after kidney donation. We wanted to perform a survey to assess how transplant professionals in Europe inform potential kidney donors regarding long-term risks. The objectives of the survey were to determine how they inform donors and to what extent, and to evaluate the degree of variation.
Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients
José Jesús Broseta, Diana Rodríguez-Espinosa, Erica Soruco, Francisco Maduell
doi : 10.1093/ndt/gfab195
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1754–1755
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort
Luc Frantzen, Guilhem Cavaillé, Sandrine Thibeaut, Yohan El-Haik
doi : 10.1093/ndt/gfab165
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1756–1757
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
Annette Bruchfeld, Andreas Kronbichler, Federico Alberici, Fernando C Fervenza, David R W Jayne, Mårten Segelmark, Vladimir Tesar, Wladimir M Szpirt
doi : 10.1093/ndt/gfab174
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1758–1760
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant
Marcia M L Kho, Marlies E J Reinders, Carla C Baan, Debbie van Baarle, Frederike J Bemelman, Dimitri A Diavatopoulos, Ron T Gansevoort, Fiona R M van der Klis, Marion P G Koopmans, A Lianne Messchendorp, Renate G van der Molen, Ester B M Remmerswaal, Nynke Rots, Priya Vart, Rory D de Vries, Luuk B Hilbrands, Jan-Stephan F Sanders, RECOVAC Collaborators
doi : 10.1093/ndt/gfab186
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Pages 1761–1764
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients
Fabio Sallustio, Claudia Curci, Nada Chaoul, Giulia Fontò, Gabriella Lauriero, Angela Picerno, Chiara Divella, Vincenzo Di Leo, Maria De Angelis, Sanae Ben Mkaddem, Luigi Macchia, Anna Gallone, Renato C Monteiro, Francesco Pesce, Loreto Gesualdo
doi : 10.1093/ndt/gfaa344
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Page 1765
The challenge of early glomerular filtration rate decline in response to antihypertensive treatment and chronic kidney disease outcomes
Lorenzo Signorini, Gianluigi Zaza, Giovanni Gambaro
doi : 10.1093/ndt/gfaa345
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Page 1766
P1627 KIDNEY TRANSPLANT OUTCOMES FOR CHILDREN AND YOUNG ADULTS IN THE UK
Alexander Hamilton, Lucy Plumb, Anna Casula, Manish D Sinha
doi : 10.1093/ndt/gfab010
Nephrology Dialysis Transplantation, Volume 36, Issue 9, September 2021, Page 1767
